Novo Nordisk A/S: Danish pharma leader in diabetes and obesity drugs (Ozempic, Wegovy).
Price
39.51
24H
—
Volume 24h
$2.96M
OI (USD)
$5.46M
Market Cap
$174.49B
| Exchange | Symbol | Mark | Index | Basis | FundingEach venue's rate is converted to an hourly equivalent. Annualized funding = hourly rate × 24 × 365 (not compounded). Multi-venue values are weighted by 24h volume. | Volume 24h | Vol % | OI (USD) | Live |
|---|---|---|---|---|---|---|---|---|---|
 | NVOUSDT | 39.51 | 39.47 | +10.9 bps | +5.32% +0.0049% / 8h · -- | $2.11M | 71.3% | $2.26M | 114d |
 | NVO_USDT | 39.53 | 39.49 | +9.4 bps | +0.00% +0.0000% / 8h · -- | $459.22K | 15.5% | $871.53K | 118d |
 | NVOUSDT | 39.49 | 39.47 | +5.1 bps | +0.00% +0.0000% / 8h · -- | $234.63K | 7.9% | $690.44K | 47d |
 | NVOSTOCK_USDT | 39.49 | 39.47 | +5.1 bps | +5.26% +0.0048% / 8h · -- | $155.17K | 5.2% | $1.64M | 114d |
News
20NVONovo Nordisk aims to keep operating margin broadly stable through 2030
×71dNVO▲Novo Nordisk says half of Wegovy U.S. sales come from cash-pay channels, while oral drugs reach 90%
×21dNVO▲Novo Nordisk is expanding into women’s and men’s health in new markets
×21dNVO▼Novo Nordisk announces 4,000 additional departures, bringing total to 13,000
1d